If you are active innovators in vaccine R & D and looking for the business development for your potential vaccine not necessary limited in China but also tremendous opportunities in front of potential investors or corporations from all over the world,
WCV 2008 provides you perfect face2face opportunities through such overload innovators' presentations and so much breakthrough showcases for your choose. You can not only meet those big pharma decision makers or the investors looking for the investment opportunities. Bring your updated Vaccine pipeline progress or even your concept proof the technologies in front of your potential customers and investors. If you have exciting discovery optioned for technology transfers, joint venture, or you have competitive service capacities in the following areas, you should take them with you to join
WCV 2008 !
"To Whom it may concern:"
1) What Bio or Pharma Business Models suitable for setting up across cultural biotech company in China?
2) How to Attract Early Stage Capital for your vaccine development?
3) How to Attract US Capital for Vaccine Development in China and beyond?
4) How are IPOs valued in China and who are buyers of Potential Vaccines?
5) The Successful Case Studies from Recent Vaccine innovators
6) How to define Your Value-added Vaccine R & D Outsourcing?
7) Current Trends in Seed & Early Stage Investing in vaccination projects or programs
8) How to draw your roadmap to run your vaccine development or production oriented business and a necessity for raising capital?
9) Can you define your valuations of your vaccine innovation to avoid a sensitive subject to VCs?
10) You already owned new expression system or Vaccine Candidate Identified
11) You have Validated Technologies for development of new vaccines or productive processes?
12) You own Screening Platform of antigens.
13) You own Novel Immunology / Animal models/Vectors / Adjuvants / Vaccine Delivery System
14) You can provide Vaccine Safety Evaluation Services
15) You are service companies to provide Regulatory/Social or legislation consultations
16) Your Vaccine Candidate enters Phase I, II or III Clinical Trials
17) You have Vaccine Production GLP or GMP Facilities
18) You have Bioinformatics R & D and Structure Based Vaccine Design Team
19) You have Vaccine R & D or Production CRO and CMO Outsourcing Capacities
20) You have Vaccine Related Virological Study Wet Labs
21) You can provide Bioanalysis of New Antigen, Immunological Studies
22) You have PK & PD Service Capacities for Vaccine Leads or Candidates
23) You have High Throughput Analytical Capacities (NMR, MS, LC-MS, or Maldi-TOF)
24) You have experiences of GCP Clinical Research & Trials for Vaccine Development,
25) Having Potential New Human Vaccines (anti-cancer, anti-infectious and non-infectious diseases),
26) Having Potential New Veterinary Vaccines (anti-infectious and non-infectious diseases),
27) Can do Translational Vaccinological Sciences
28) Have GLP/GMP Vaccine Bioprocess Engineering Capacity
29) Have FDA inspected lab with Animal Resources for vaccine studies
30) Have FDA Acceptable Clinical Trial Support Capacities
31) Have Inspected GMP/GCP Facilities
32) Can provide GLP/GMP Production/Manufacturing of vaccine candidates
33) You are the innovator possessing other unique technologies or products to support vaccine discovery
If you are interested in bring your vaccine innovations to our colleagues and your potential partners, customers or your investors,
Join us Now!
Contacts:
